Spearhead Bio

Cell & Gene Therapy · Biotechnology
$6.2Mtotal raised · 3 rounds on record
$1.2Mlatest round · Convertible Note · Jun 2026 · 4 mo ago
10+team · employees, estimated range
2024founded

Overview

We harness the power of programmable transposable elements to replace, insert, copy, rearrange, and stack large DNA sequences into plant genomes.

Funding and backers

Total raised
$6.2M
3 rounds on record
Latest round
$1.2M
Convertible Note · Jun 2026 · 4 mo ago
Team
11-50
employees, estimated range
The money's age
Fresh money
4 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 18 Raised a round Convertible Note $1.2M · SEC Form D Feb 2 Raised a round Venture round $4M Feb 6, 2025 Raised a round Convertible Note $1M · SEC Form D 2024 Founded
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note Jun 2026 $1.2M — SEC Form D
Venture round Feb 2026 $4M — brdgpark.com
Convertible Note Feb 2025 $1M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Spearhead Bio, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Michael BielskiExecutive Officer, DirectorSEC Form D
Keith SlotkinExecutive Officer, DirectorSEC Form D
Harold DaviesExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Kilobaser, Industrial Microbes
Andreessen Horowitz
backs ElegenBio, Mana.bio
ARCH Venture Partners
backs Qihan Biotech
RA Capital Management
backs Metagenomi
NFX
backs Mana.bio
Globis Capital Partners
backs Logomix
Similar startupsby what they do, their industry and backers
EditCoFounded 2018
EditCo provides CRISPR gene editing services, CRISPR products & genome engineering solutions for disease models, drug discovery and cell…
ElegenBioVenture round $33M · 2 yr ago
Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured…
Logomix8 roles
Logomix is a Japan-based synthetic biology company that develops genome engineering technologies for human cells. Its Geno-Writing platform…
Industrial Microbes51-200 employees
IMicrobes: Accelerating the transition to sustainable materials through synthetic biology -Our programmable microbes turn ethanol into…
Qihan BiotechFounded 2017
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome…
Mana.bio51-200 employees
Mana.bio is an AI-based drug delivery startup specializing in programmable drug delivery and gene therapy, with a focus on lipid…

Financials

Total raised
$6.2M
Latest round
Convertible Note
Funding rounds
3
Funding rounds
Round Announced Amount
Convertible Note 2026 $1.2M Details
Venture - Series Unknown 2026 $4M Details
Convertible Note 2025 $1M Details

People

Michael Bielski
Executive Officer, Director
SEC Form D
Keith Slotkin
Executive Officer, Director
SEC Form D
Harold Davies
Executive Officer, Director
SEC Form D
Thomas Laurita
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Saint Louis United States
HQ
10-50 est. staff
975 N. Warson Road, St. Louis, MO 63132
company site